ReviewCurrent nutrition reports2025
Role of Galangin for the Treatment of Alzheimer's Disease: Journey So Far and Road Ahead.
Review in Current nutrition reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewAlzheimer’s disease (AD) is a progressive neurodegenerative disease (NDs) that primarily affects cognitive function, with memory loss, impaired judgment, and difficulties in learning and language being prevalent among affected individuals. Currently available treatments, such as parasympathomimetic drugs, N-methyl-D-aspartate (NMDA) glutamate receptor antagonists, and monoclonal antibodies, only provide symptomatic relief. However, they are associated with side effects on long-term use. Hence, a safe and effective treatment can be achieved using plant-based bioactives such as galangin (GAL). RECENT
findingsAmong them, GAL, a flavonol, deciphers potent neuroprotective effects. GAL possesses anti-amyloid, antitau, antioxidant, anti-inflammatory, and anti-cholinesterase effects. Moreover, it also attenuates mitochondrial dysfunction and neuronal cell apoptosis. Despite showing such neuroprotective effects, GAL shows a low dissolution profile, leading to poor bioavailability of the drug in the brain. In the last few decades, novel drug delivery systems (NDDS) have shown significant responses to overcome the limitations of conventional delivery of lipophilic drugs. Nanoformulations exhibit many advantages such as easy preparation, high drug loading, high stability, enhanced loaded drug efficacy, and better drug delivery at the target site. Several databases have been searched, such as Sciencedirect, Pubmed, Google Scholar, with the keywords “galangin”, “Alzheimer’s disease”, and “Nanoformulation”. Among them, 200 articles were found relevant to the proposed study, where 146 selective articles were referred for preparing the manuscript. The present review has entailed about the mechanism through which GAL shows a neuroprotective role in treating AD. However, NDDS loaded with GAL has shown significant benefits over conventional oral administration. Despite having promising potential of GAL against NDs in its naïve form as well as in the form of nanoformulations, its translation into a marketed product is limited due to stability and scalability. A better understanding of mechanistic pathways and integrity of drug-loaded nanoformulations within the biological fluids, as well as analyzing the challenges at the BBB interface related to permeation and site specificity, would offer a translational nanomedicine of GAL for treating NDs, especially AD.
Indexed as
Identifiers
40526360What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.